Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes

Journal article

Open access

Peer reviewed

Mikkael A Sekeres, Christine O'KEEFE, Alan F List, Katarina Paulic, Manuel Afable, Ricki Englehaupt and Jaroslaw P Maciejewski

American journal of hematology, Vol.86(1), pp.102-103

2011

PMID: 21080340

Abstract

Biological and medical sciences

Hematologic and hematopoietic diseases

Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis

Medical sciences

url

https://www.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.21891View

Published (Version of record) Open

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.155 Acute Myeloid Leukemia
Web Of Science research areas: Hematology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
Creators: Mikkael A Sekeres - Cleveland Clinic
Christine O'KEEFE - Cleveland Clinic
Alan F List - Moffitt Cancer Center
Katarina Paulic - Cleveland Clinic
Manuel Afable - Cleveland Clinic
Ricki Englehaupt - Cleveland Clinic
Jaroslaw P Maciejewski - Cleveland Clinic
Publication Details: American journal of hematology, Vol.86(1), pp.102-103
Publisher: Wiley-Liss
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 21080340
Record Identifier: 991031757938402976